INTRODUCTION
The prize-winning essayist and physician/scientist, Lewis Thomas, wrote that the secret to a 'long, contented life in the laboratory is to have a chronic insoluble problem and keep working at it'. 1 Following his own advice, Thomas chose to work on endotoxin, specifically the pathogenesis of the Shwartzman reaction. 2 While many investigators since Thomas have elected to work on various aspects of endotoxin, perhaps few topics within that field remain as puzzling as the phenomenon of 'endotoxin tolerance'. Ivan Bennett noted that the phenomenon of endotoxin tolerance is experimentally so remarkable that it is difficult to believe it has no clinical significance. 3 In recent years, with the identification of an increasing number of intracellular signalling molecules, there has been an explosion of published research describing the up-and down-regulation of these proteins following LPS exposure, as well as the 'cross-talk' between the signalling pathways and their potential role in endotoxin tolerance. Yet the essential nature of endotoxin tolerance and, more importantly, its physiological significance remains as elusive today as it was when first described. In this manuscript, using the perspective of studies performed in the precytokine era, I will review the transition of endotoxin tolerance research from the mostly in vivo studies of that era to the predominantly in vitro studies of today. I will conclude that important unresolved issues of the earlier era remain relevant today, and that methodological concerns in the conduct of contemporary studies must be rigorously addressed.
EARLY STUDIES
While there are many conditions or reagents that can diminish the host response to endotoxin, in its simplest terms 'endotoxin tolerance' refers to a hyporesponsive state following a second or additional doses of endotoxin in contrast to the responses observed after an initial exposure to endotoxin. Endotoxin tolerance became a practical problem in the late 1940s, when the active principal from Coley's toxin, lipopolysaccharide (LPS, then called 'polysaccharide') was tested as a potential therapy for cancer and, when repetitive administration of typhoid vaccine was used, as fever therapy. 4, 5 A single dose of endotoxin elicited hemorrhagic necrosis in tumor tissue. It was soon appreciated that after daily doses of LPS, the responsiveness became greatly diminished and the need to develop strategies to avert this situation was recognized (S.E. Griesman, personal communication). This decreased responsiveness to repetitive doses of LPS in cancer patients was confirmed in more recent studies of LPS therapy. 6, 7 In his classic studies, Beeson demonstrated that repeated daily injections of endotoxin to rabbits resulted in a progressive reduction in the LPS-induced febrile or pyrogenic response. 5 He postulated the existence of an endogenous pyrogen and isolated material from human leukocytes that induced fever. 8 Beeson went on to demonstrate that pyrogenic tolerance was associated with an increased clearance of LPS from the blood and that blockade of the reticulo-endothelial system (RES) by particulate matter, such as India ink or thorium dioxide, rapidly reversed the endotoxin tolerance. He concluded that endotoxin tolerance may be associated with an increase in RES activity. 9 These observations on the potential importance of the RES in LPS responses were strengthened when a number of investigators in the 1950s showed that a single dose of endotoxin increased the ability of the RES to clear bacteria and non-viable particulate matter from the bloodstream, [10] [11] [12] lending support to the idea that endotoxin tolerance might be due to a more rapid clearance of a second dose of endotoxin from the bloodstream and its inactivation by the RES.
Using fever induction as an end-point, two types of endotoxin tolerance were recognized. 13 Early tolerance (< 72 h) was considered non-specific in that the endotoxin derived from different bacterial species could initiate the RES activity and the non-responsiveness was observed following the administration of heterologous LPS (but not with other microbial products). Different targets (e.g. Gram-positive bacteria, inert particles such as India ink) could be cleared by the LPS-stimulated RES. 14 It was transient and not transferable by serum. Late tolerance (> 72 h), probably due to the development of O-specific antibody, was both type-specific and transferable. Griesman found that in rabbits and in man, in as much as splenectomy had no impact on the pyrogenic response to LPS infusion, the spleen had no role in the early pyrogenic tolerance to LPS, but that the spleen had an important role in the late tolerance (probably due to its role in antibody formation). 15 He later showed that Oantigen of LPS, responsible for type-specific immunity (i.e. no lipid A), conjugated to a carrier protein was unable to induce tolerance. 16 Further reference in this review to endotoxin tolerance refers only to the early tolerance, unless stated otherwise.
The ability of a single dose of LPS to enhance RES activity and thereby remove (i) LPS more rapidly perhaps leading to endotoxin tolerance, and (ii) bacteria more rapidly leading to increased survival from infection was noted nearly a half century ago. [10] [11] [12] The potential significance of this duality in LPS response is still not fully appreciated. A single dose of endotoxin also renders experimental animals less susceptible to infection with influenza, lethal doses of gamma irradiation and hemorrhagic shock. [17] [18] [19] Conceptually, it would be quite appealing if a single mechanism, the enhanced RES activity, could explain both the reduced responsiveness to LPS and improved antibacterial host defenses. However, in a series of studies in both animals and several hundred human subjects that were as thoughtful as they were thorough, Griesman and colleagues challenged that hypothesis. They noted that in man, the enhanced activity of the RES alone was insufficient to explain LPS tolerance, since LPS did not increase the clearance of aggregated human serum albumen from the circulation. 20 Further, by inducing RE blockade in both animals made tolerant to LPS as well as non-tolerant animals, Griesman (and later Wolff 21 ) found that striking differences in reactivity to LPS persisted between tolerant and non-tolerant animals. LPS tolerant animals still were able to mount a fever in response to LPS. This suggested that there were other factors besides the RE blockade in the mechanism of tolerance induction. In other experiments designed to simulate the enhanced clearance of LPS by the RES from the circulation of tolerant animals, he administered an LD 80 dose of LPS intravenously to rabbits and performed exchange transfusions 20 min later to remove the circulating endotoxin. 22 LPS lethality in these non-tolerant animals could not be prevented even though the circulating levels of LPS were reduced to levels equivalent to those observed in tolerant animals that survived this dose. He concluded that it was not the enhanced uptake of LPS by the RES but rather the enhanced resistance of cells in the RES to the LPS toxicity. In short, the RES clearance, even if it occurred in man, did not adequately explain endotoxin tolerance.
The hepatic uptake of LPS by the liver had been well-documented. 23 In 1968 Dinarello, Bodel and Atkins demonstrated the importance of the liver in the development of pyrogenic tolerance by showing isolated hepatic macrophages, Kupffer cells, stimulated in vitro with LPS elaborated an endogenous pyrogen 24 and that these cells from tolerant rabbits were unable to release endogenous pyrogen following exposure to LPS. Griesman directly tested the hypothesis that tolerance was based on a reduced responsiveness of Kupffer cells to LPS. Infusing LPS into the portal vein of rabbits, he showed that the pyrogenic response was due to the hepatic release of an endogenous pyrogen and that tolerant animals were refractory to that release. 25 This refractory state of hepatic Kupffer cells to the generation and release of endogenous pyrogen presumably persisted after RES blockade and might have explained the refractoriness of the liver to LPS despite the blockade. In this interpretation, the accelerated RES clearance simply may have diverted the LPS away from other target organs and more rapidly to the refractory Kupffer cells. With RE blockade, he speculated that the LPS was shunted to macrophages in other tissues to account for the persistent fever. In an interesting study, Griesman and colleagues were able to induce endotoxin tolerance during overt tularemia and typhoid infections (i.e. tolerance mechanisms were maintained during infection) and showed an accelerated clearance of [ 51 Cr]-labelled LPS as pyrogen tolerance was induced. 26 Since the deliberate induction of endotoxin tolerance did not mitigate the clinical manifestations of the infection, he concluded that circulating LPS was not the major cause of fever and toxemia during this illness. Earlier, other investigators found an endotoxin tolerant state after injection of LPS or killed Gram-negative bacteria to patients with chronic pyelonephritis, 27 convalescent from typhoid or paratyphoid fever, 28 patients recovering from malaria, 29 and in subjects inoculated either with live Salmonella typhosa 30 or with Plasmodium cynomolgi. 31 
Early studies of LPS-induced mediators
One of the earliest inflammatory mediators to be studied in LPS-initiated immune responses in general and in endotoxin tolerance in particular, was 'endogenous pyrogen'. It became evident that the activity of LPS was dependent on its induction of a mediator molecule(s). Beeson extracted pyrogenic material, termed 'endogenous pyrogen', from neutrophils; 9 however, since fever developed in neutropenic patients after LPS challenge and endotoxin tolerance developed in the complete absence of neutrophils, additional sources of endogenous pyrogen were considered. 32 The work of Wood, then Atkins and Bodel and later that of Griesman, demonstrated endogenous pyrogen in human monocytes. 25, 33, 34 It was not clear whether investigators at the time considered that endogenous pyrogen had activities beyond its fever-inducing properties. While LPS is now known to induce cytokines, such as IL-1 and TNF-a, that alter thermoregulation, the spectrum and nature of potential endogenous pyrogens remains to be characterized fully.
Cytokines
Long before the recognition of TNF-a and IL-1 in the 1980s, the effect of LPS tolerance induction on cytokine expression was described. Ho and colleagues 35 as well as Youngner et al. 36 observed that with LPS tolerance there was a decrease in interferon (IFN) induction with repetitive doses of LPS. It also was found that poly-I, poly-C, an IFN-g stimulator, mimicked LPS, 37 and that multiple injections of this compound, or LPS itself, induced interferon tolerance. 38 Colony-stimulating activity (CSA) was one of the earliest mediators identified to play a role in LPS tolerance. 39 Decreased CSA was observed in animals after a single or multiple injections of LPS i.v. or i.p. Later, this refractory state was shown to be overcome by increasing the dose of LPS. 40 Although such mice had decreasing CSA, there was a marked granulocytic hyperplasia in the bone marrow and a normal release of neutrophils from the bone marrow. 39 This granulocytosis following repetitive doses of LPS was also observed in cancer patients. 6 Thus the release of PMN from the bone marrow after LPS may be separate from its effect on CSA. 39 Vogel's laboratory observed that repeated doses of endotoxin led to increased CSA and an increase in the bone marrow macrophage precursor pool, suggesting that the increased numbers of these immature cells may play a role in the impaired responses to LPS. 41, 42 Later, recombinant IL-1 receptor antagonist (IL-1ra) was shown to block both CSA activity and tolerance induction, 43 implicating a role for IL-1 in the process.
By the late 1970s, the broad outlines of endotoxin tolerance had been described: (i) it was a state of relative non-reactivity to the fever-producing effect of a bacterial pyrogen inducible within 48 h, but could persist for weeks; 5 (ii) hepatic macrophages (Kupffer cells) appeared to play a central role; and (iii) it probably involved the decreased generation of an LPS-inducible mediator, endogenous pyrogen, even though LPS was detectable in the circulation, but that other mediator activities, such as interferon production and colony stimulating activity, were also affected. Tolerant animals remained responsive to preformed endogenous pyrogen.
Through advances in our understanding of the LPS molecule, the active principle was attributable to the lipid A portion of the molecule. 44 Endotoxin tolerance was also known to be non-specific in that the induction of tolerance with one phenotype of LPS could induce the tolerant state demonstrable with a heterologous LPS. Chedid and colleagues later explored whether another fever-inducing molecule, synthetic muramyl dipeptide (MDP), shared the ability to induce tolerance. Although MDP and LPS both induced CSA, the former even in C3H/HeJ mice, 45 MDP and LPS were not cross-tolerant with regard to fever. 46 Co-administration of LPS and MDP synergistically induced CSA. Repetitive doses of MDP continued to induce CSA. It is now appreciated that MDP probably reacts with macrophages through Toll-like receptor (TLR) 2 while LPS does so through TLR4. Thus, these studies may have been among the earliest to explore the differences between TLRs in eukaryotic responses.
There was conflicting evidence on the potential role of enhanced RES activity. Griesman's studies did not definitively exclude the importance of enhanced RE clearance as a mechanism in endotoxin tolerance. It is difficult to know if Griesman's choice of albumen rather than bacteria or some other target requiring a surface receptor that is modulated by LPS may have explained his failure to detect enhanced clearance by the RES, but he did later show accelerated clearance of radiolabelled LPS in man during tolerance induction. 26 Alternatively, as he suggested, the RES response of human subjects to LPS may differ substantially from those responses in rabbits or rodents. Certainly, the administration of an LD 80 dose of LPS could have initiated a mediator cascade before the removal of large amounts of blood (and LPS) by exchange transfusions were performed 20 min later. Thus, the reduction of LPS by exchange transfusion might not have been able to reverse the tolerance induction following the initial LPS exposure. Nevertheless, the finding of differences in pyrogenic responses after the induction of RE blockade in tolerant and non-tolerant animals is consistent with the hypothesis that a refractory state persisted despite the blockade; he was able to support this contention by showing a decrease in mediator (endogenous pyrogen) production. 20 Finally, additional reports questioned the role of RES activity by showing the protective effect of LPS against M. fortuitum lasted longer than the LPS-induced increase in RES activity, and that while zymosan (yeast cell wall) increased the size of the RES, it did not have the same protective effect of LPS (however, zymosan may not have activated the Kupffer cells as does LPS). 47, 48 Thus, the relationship between endotoxin tolerance and RES activity was unresolved.
CONTEMPORARY STUDIES OF ENDOTOXIN TOLERANCE
During the next two decades, dramatic progress was made in our understanding of the molecular and cellular effects of LPS to the extent that now the level of expression of these molecular and cellular responses in vitro have largely replaced gross physiological end-points, such as fever or animal lethality, as measures of endotoxin tolerance. 49 In the case of man, there were few parameters to follow that were of sufficiently low risk. The various molecular responses that have been examined during conditions of LPS tolerance induction are listed in Tables 1-3. A detailed analysis that focuses on the changes in the intracellular expression of these molecules and the interplay among the different signalling pathways following LPS exposure is beyond the scope of this review.
As the important role of TNF-a and IL-1 in LPSmediated responses became appreciated in the 1980s, the reduced expression of these and other cytokines, as well as non-cytokine mediators, both in vivo and in vitro following a second dose of LPS was soon noted. 50, 51 With the recognition that LPS and inflammatory mediators signalled the cells through surface receptors, investigators discovered that the surface expression of these and other receptors could be modulated by previous exposure to LPS or inflammatory mediators. 52 The down-regulation of these receptors could explain, in part, the responsiveness to a second dose of LPS. 42, 53 Finally, as the transduction pathways through which surface signals instructed the cellular responses and the activation of genes involved in that response were defined, decreased expression or refractoriness of the protein components of those pathways also were observed. 53 For example, decreased levels of GTP binding proteins, 54, 55 MAP kinases, 53, 56, 57 and the transcriptional factor NF kB 53, [58] [59] [60] [61] have also been demonstrated during LPS tolerance. It also became apparent that the induction of LPS tolerance was not a global hyporesponsiveness to all agonists following LPS treatment but a specific adaptation to that molecule with not only decreased but also increased responses. During the induction of tolerance there may be an increased expression of IL-1ra (shown in both human PBMCs and in THP-1 cells 62, 63 and in a number of signalling proteins) ( Table 2 ). The NF-kB subunit (p50) was up-regulated during LPS tolerance and blocked TNF-a gene expression since p50 binds to DNA but lacks a trans-activating domain. 64 There is also an increase in the expression of IkBa during endotoxin tolerance, [65] [66] [67] [68] as well as a lack of its phosphorylation. 69 Based on the earlier demonstration of the role of Kupffer cells and the later demonstration that endotoxin tolerance could be transferred experimentally through the adoptive transfer of macrophages, 70 in vitro experimental systems were developed for the study of endotoxin tolerance that employed primary monocytes or human and murine macrophage cell lines.
Levels of LPS-induced mediators in endotoxin tolerance
With the characterization of cloned cytokines, it is now clear that there are a number of cytokines that could have been 'endogenous pyrogens' based on their ability to directly stimulate hypothalamic PGE 2 synthesis. 71 One measure of the LPS tolerant state is the reduced expression of cytokines following an 'eliciting' dose of LPS. This has been well-documented in vitro, in vivo and ex vivo (i.e. removal of cells from an LPS-treated subject and then stimulated in vitro). Significantly, the ex vivo stimulation of cells obtained from septic patients with LPS has shown a decreased cytokine expression. [72] [73] [74] [75] Of interest, however, is that even during endotoxin tolerance, there are some cellular responses that are not decreased (see Table 2 ), while still other responses have varied in different reports (Table 3) . IL-6 and acute phase reactants (APR) may decrease 76, 77 or increase with repetitive LPS treatments. 78, 79 Similarly, IL-1 has shown a variable response. 57, 58, 80, 81 Some studies have also demonstrated only minimal reduction in IL-1. 80 This latter observation may be of potential significance in that IFN-g is usually not produced by macrophages, which are the cells primarily employed in in vitro studies of LPS tolerance. Thus, an emphasis on in vitro systems of LPS tolerance may overlook important contributions of other cell types (see below). Studies in both humans and rodents have observed little downregulation in the expression of some chemokines, particularly IL-8, [82] [83] [84] while others report an increase, 52, 85 and still others a decrease. 86 The down-regulation of IL-12 during LPS tolerance does not appear to depend on IL-10 or TGF-b, 87 and may depend in part on the loss of CD11c high dendritic cells. 88 Perhaps most puzzling is the IL-10 response. It might be expected that with repetitive LPS administration there would be an increase in IL-10 expression which would then 'turn off' further LPS-mediated responses, but the data are not so definitive. While some have demonstrated increased expression of IL-10 and IL-10 receptor, 89, 90 a decrease in IL-10 was shown during the ex vivo stimulation of PBMCs of human subjects given LPS 91 and of cultured human PBMCs. 87 Nor is the role of IL-10 clarified by further experimentation. IL-10 knockout
Endotoxin tolerance -current concepts in historical perspective 87 mice could be made tolerant to LPS and administration of exogenous recombinant IL-10 did not alter this finding. 92 It was concluded that, unlike its role in defenses against the pathological responses to LPS, it is not responsible for LPS-induced tolerance. Treatment with a combination of monoclonal antibodies to both IL-10 and TGF-b however, prevented the induction of a tolerant state. 87 Finally, comparison of LPS tolerance with IL-10-induced hyporesponsiveness to LPS showed clear differences in molecular mechanisms. 94 Undoubtedly, some of these conflicting data may be attributable to the different times after LPS exposure that the samples are drawn (see below). Depending on the dose and timing, pretreatment of mice with TNF-a protected against a lethal dose of LPS (and of TNF), suggesting that there may be cross-tolerance that persisted for up to 2 weeks. 87 Although TNF RI/II double knockout mice can be tolerized to LPS, the role of TNF in LPS tolerance is still not clearly defined. 95 
Induction and reversal of tolerance by recombinant cytokines
While it has been stated that one cannot induce the LPS tolerant state by cytokines alone, 80 others have shown that while either cytokine alone was unable to induce tolerance, the combination of recombinant IL-1 and TNF-a reduced the CSA and increased the number of macrophage precursors in the bone marrow after LPS, 42 responses observed with LPS tolerance induction. The combination IL-10 and TGF-b is reported to induce a tolerant state. 62 A number of studies have documented the ability of various cytokines to break established endotoxin tolerance. The differences in responses to the various treatments used to break LPS-induced tolerance suggest divergent pathways of cytokine regulation among those cytokines induced by LPS (e.g. IL-1, IL-6, IL-12 and TNF-a). IFN-g, GM-CSF and IL-12 can reverse endotoxin tolerance in vitro 96, 97 and in vivo. 98 Interestingly, the decreased IL-12 response of LPS tolerized cells is not rescued by either IFN-g or GM-CSF. 87 Administration of IFN-b induced TNF-a in tolerized rabbits, and broke pyrogenic tolerance. 99 While IFN-g inhibits the induction of LPS tolerance, neither IFN-a nor IFN-b can do so. 96 While not a cytokine, the protein kinase C activator, phorbol ester, reversed the refractoriness of MAPK and p38 kinase activation as well as IL-6 expression in LPS tolerant cells. 56, 76 There are conflicting data on the ability of phorbol ester reversing TNF-a secretion, however. 76, 100 
Specificity
Early studies that employed fever as an end-point demonstrated that LPS tolerance was not a global hyporesponsiveness to stimuli, but rather a specific adaptation to that molecule. Likewise, many molecular markers of endotoxin tolerance that fail to respond normally to a triggering dose of LPS in endotoxin tolerant systems, are expressed when the second signal is not LPS (e.g. peptidoglycan); 101,102 however, with the greater sensitivity of the present methods used to detect differences in their expression, it is possible to detect various degrees of hyporesponsiveness to these non-LPS stimuli than was possible using fever as the measure. [103] [104] [105] [106] [107] [108] The in vivo significance of these in vitro observations remains to be elucidated.
EXPERIMENTAL CONSIDERATIONS IN THE STUDY

OF ENDOTOXIN TOLERANCE
While it is clearly possible to induce endotoxin tolerance both in vitro and in vivo and to document its clinical occurrence (see above), its biological significance remains elusive. Moreover, with the burgeoning literature, there is a great deal of conflicting data being generated. With interest in adapting endotoxin tolerance to the clinical realm in the treatment or prevention of sepsis, there is now a need to examine critically the experimental conditions employed in these studies in an attempt to explain the sources of discrepancies in the literature.
LPS dose
The justification or rationale for the selection of a particular dose of LPS for either the induction or triggering (i.e. the dose of LPS used to elicit a response in LPS tolerant systems) is often lacking. This can be a critical decision since the LPS tolerant state is relative (at least with regard to fever) and can be reversed by higher doses of LPS. The outcome following a triggering dose of LPS is related to the dose of LPS initially administered. 13, 49 Moreover, the dose of 'triggering' LPS (to be blocked by the tolerizing LPS regimen) is usually dictated by the response under study (e.g. fever or endotoxin-induced lethality). Thus, for the febrile response, the pyrogeninducing dose may be quite low (temperature elevations in man and rabbits are elicited by < 1 ng/kg, 13, 21 ) or quite high if endotoxemic lethality is the measure (e.g. 20 mg/kg). 49, 109 While rabbits require 10 times the dose of LPS to achieve the same elevation in temperature as man, in both man and rabbits, tolerance to both the pyrogenic and toxic manifestations of LPS can be overcome by increased doses of LPS. 13, 21 Consequently, the dose of LPS used for the induction of endotoxin tolerance should bear some relationship to the threshold dose of LPS required for the triggering response. If a goal of studies of endotoxin tolerance is to further our understanding of the mechanisms and to assess its potential significance to living systems, one must consider the levels of LPS likely to be encountered in nature. For example, 10 9 CFU of Escherichia coli contains approximately 2.5 mg of LPS. 110 During bacteremia in humans, colony counts rarely exceed 10 4 CFU/ml of blood, with 10 7 CFU/ml the highest reported bacterial concentration in the blood. 111, 112 This corresponds to circulating LPS levels of barely 1 mg in man and low nanogram to sub-nanogram levels in mice. Further, in moribund mice there was approximately 10 9 CFU/g tissue. 113 Consequently, in a 25 g mouse at death, there would be the equivalent of less than 65 mg of endotoxin as the total body LPS load, which is far below the lethality levels for most strains of mice. With our developing knowledge of the potential synergistic role of other bacterial products in the host response to bacteria, it is possible that microbial DNA, outer membrane proteins or toxins that behave as superantigens lethally synergize with the LPS-induced responses, as suggested by others. 114, 115 There are little data on the possible role of LPS tolerance in modulating the host response in the event that the LPS is presented within the context of an intact organism. This information may be particularly important in understanding the susceptibility to infection if the induction of tolerance is contemplated for the prevention or treatment of sepsis.
Recent studies appropriately have focused on relatively pure microbial products as agonists or ligands in order to understand the cell surface receptors through which these specific products elicit a response. Bacteria may interact with TLR4 (LPS), TLR2 (lipoproteins, peptidoglycans), TLR5 (flagellin), and TLR9 (DNA; for review, see Aderem 116 ). More recently, there has been interest in studying the molecular interactions when separate signalling pathways, such as TLR2 and TLR4 or TLR4 and TLR9, are activated. 107, 115, 116 Given the welldocumented specificity of the LPS tolerant state as well as the potential interactions among signalling pathways, it will be important to determine the outcome of encounters between bacteria and endotoxin-tolerized cells, and the impact of LPS when presented to the cells as components of bacteria during infection.
Schedules
Tolerance to both the febrile and toxic manifestations of LPS can be established after a single 13, 39, 41, 44, 99 or two 99, 117 daily doses with a peak effect at 2-4 days and a normal response returning by day 8 or earlier after initial LPS. 41 Continuous intravenous infusion of endotoxin to human subjects leads to a tolerant state within hours such that the individuals 'express disbelief' the LPS infusion is continuing. 13 Various regimens have been employed for tolerance induction with single daily injections for up to 7 days or longer (e.g. every 3 days for 5 doses, or every day for 25 days or 150 mg twice daily for 7 days) being employed. 117, 118 Beeson noted that maximum pyrogenic tolerance required repetitive, closely spaced injections. 5 There are relatively few recent studies, however, comparing the effect of differing inducing regimens (both the different frequency of LPS administration or different dose) on the depth or duration of tolerance, particularly using molecular markers. For in vitro studies. the duration of LPS treatments have ranged from 4 h 52 to 2 days. 90 These differences may be important if endotoxin tolerance is applied to the clinical realm. Based on the clinical setting, the exposure to LPS may be brief or chronic, with different implications for the induction and maintenance of endotoxin tolerance. Importantly, as the intervals between LPS challenge are lengthened, the late, antibody-dependent endotoxin tolerance will develop, and may co-exist with the early tolerance. 13 This may also be true of repetitive daily dosing over a several day interval. It may, therefore, be difficult to separate the contributions of antibody-independent and dependent tolerance.
Breaking or decline from tolerance
Once established, LPS tolerance may persist for up to 30 days after discontinuing the LPS, 5,119 depending on the parameter used to measure the presence of tolerance. Few studies systematically address the molecular events involved in the recovery from established LPS tolerance, however, and correlate those events with some in vivo parameter. This may be particularly difficult given the variety of tolerizing regimens currently in use and the possibility of a contribution from the late endotoxin tolerance.
Increasing the dose (or rate of infusion) of endotoxin can overcome endotoxin tolerance. 40 It is also possible to overcome established tolerance in man by administering half of the daily tolerizing dose of LPS 2 h after administering the first half. 120 A Danysz-like reaction has been invoked to explain this phenomenon, whereby the first half dose binds protective antibody that may be present so that the second half may act without inhibition. This Danysz-like reaction is not demonstrable in the rabbit, however. Studies of the mechanisms involved either in breaking tolerance or in the recovery from tolerance may be as instructive as those involving tolerance induction, yet there are relatively few studies that systematically analyze the mechanisms whereby tolerance may be broken by increasing doses of LPS. In contrast, a number of studies have shown that tolerance can be broken by the addition of the cytokines IFN-g or GM-CSF, or by phorbol esters that directly activate protein kinase C (see below).
Kinetics
Perhaps the most difficult aspect of interpreting studies of LPS tolerance is in the kinetics. Following the induction of endotoxin tolerance, many studies examine responses at a particular point in time both in vivo and in vitro, but examination of events at one or only a few time points would make interpretation of the data virtually impossible. This may explain the conflicting data with IL-10 (see above). LPS tolerance is a dynamic, not a static, state characterized by constantly changing levels of circulating mediators, changes in expression of cell surface molecules and refractoriness of signalling molecules. Early studies of endotoxin tolerance in vivo clearly established that there were dynamic responses in both the induction of endotoxin tolerance which usually began within 24 h of the first dose, 21 peaked at 48-96 h and then decreased in intensity over a period of days to weeks (depending on the parameter measured). For example, the TNF-a response may take up to 15 days. 121 Over a half century ago, Wharton and Creech defined a biphasic type of anti-bacterial response to a single dose of LPS subsequently used to induce endotoxin tolerance. 10 They observed a period of maximal response at 2-3 days followed by a period of hyporesponsiveness at 7 days (not unlike the 'immune paralysis' described for some patients in sepsis during which time the patient may be at increased risk of bacterial infection 88, 98 ). Thus, the immune paralysis of sepsis may represent time points in a biphasic response to LPS. If the induction of an endotoxin tolerant state is contemplated for clinical application, there must be consideration given to the constantly changing state of LPS responsiveness and to the need for its monitoring.
Many molecular correlates of endotoxin tolerance have been defined; however, each molecule examined may have kinetics that differ from other molecules also used as a measure of the LPS tolerant state. The relationships among these potentially differing kinetics must be examined if one is to understand their significance. This is best illustrated by studies that examine changes in cell surface receptors.
Recent studies of TLR4 and CD14 expression are excellent examples of the dynamic changes that occur after LPS. Studies with radiolabelled LPS demonstrated a decreased binding of LPS to macrophages made tolerant to LPS. 122, 123 In one example, a state of LPS tolerance was found to precede a down-regulation in CD14. 121 In another study, following an initial LPS exposure, there was a down-regulation of TLR4 within 24 h; however, TLR4 expression began to increase within 72-96 h despite repeated observations of LPS tolerance persisting beyond that time. It would be of interest to determine whether signalling molecules in the TLR4 pathway have similar kinetics as the receptor (personal observa-tions). 107, 124 Using TNF-a as the readout, it has been proposed that while TLR4-mediated tolerance is associated with a decrease in its surface expression, TLR2-mediated tolerance is associated with a refractoriness of its signal transduction pathway. 107 The refractory state of some key LPS signal transducing molecules downstream from the LPS receptor on the cell membrane has been proposed as one mechanism of endotoxin tolerance. A study in Chinese hamster ovary cell/CD14 cells overexpressing TLR2 and TLR4, found no difference in TLR expression during tolerance but a decrease in the transcriptional factor, NF-kB. 105 Using these CHO cell constructs overexpressing TLR4, Medvedev and colleagues demonstrated that changes in TLR4 expression could not completely explain LPS tolerance. 105 
Role of cells other than macrophages
Work by Atkins, Bodel and Dinarello and confirmed by Griesman established the Kupffer cell, hepatic macrophages, as central to LPS responses in vivo. 24, 25 Freudenberg et al. demonstrated the importance of the macrophage in these responses. 70, 125 Macrophages from the LPS responsive C3H/HeN mice, when transferred to the LPS hyporesponsive C3H/HeJ mice, conferred both lethal and tolerizing responses to LPS. 70 Further evidence of the role of macrophages was demonstrated by the ability of intraperitoneal spleen cells of non-tolerant mice to restore LPS-induced CSA generation in tolerant mice. This capacity is lost if the spleen cells are depleted of macrophages. 126 Vogel also noted that the induction of LPS tolerance was associated with an increase in the bone marrow macrophage pool, and suggested that the lack of response of LPS by macrophages may be due to a failure of these immature cells to respond to LPS. 41 Other cells may have an important role in the LPS tolerant state; however, Vogel and colleagues showed that LPS tolerance could be induced in asplenic mice as well as mice deficient in T-cells and in B-cells. 127 LPS tolerant macrophages are unable to induce IFN-g production by T-and NK-cells, whereas T-and NK-cells from LPS tolerant animals do make IFN-g when co-cultured with control macrophages. 89 Examination of the proliferative response to mitogens, a decreased response was measured in the presence of tolerant macrophages, which returned to normal if those macrophages were removed. 128 In human subjects, repetitive administration of LPS to patients with cancer showed alteration in their CD4/CD8 ratio and an increase in TNF-b (lymphotoxin) production, indicative of lymphocyte activation. 129 Impaired antigen presentation was observed by human monocytes obtained during endotoxin tolerance. 130 Dendritic and endothelial cells are now recognized as participating in the response to LPS. Endotoxin tolerance can be induced in dendritic cells, with a decreased production of IL-10, IL-12 and TNF. 82, 88 During the tolerant state, some DC functions are retained, however. During the LPS tolerant state, endothelial cells have a reduced expression of NF-kB and E-selectin, no change in ICAM1 expression and a reduced ability to support the adhesion of PMNs. 131 Although McCall and colleagues found evidence in human PMNs for a LPS tolerant state in examining IL-1 response, 132 Marie and colleagues could not find good evidence of LPS tolerance in PMNs when studying human PMNs ex vivo. 133 Interestingly, unlike the case for isolated Kupffer cells, blood leukocytes from rabbits tolerant to LPS retained an ability to release endogenous pyrogen after LPS treatment. 22 
Routes/anatomical sites
Endotoxin tolerance can be induced experimentally by both the i.v. and i.p routes. 39 Early studies established that in healthy adults the administration of 0.1-1 ng/0.1 ml of LPS intradermally will elicit a gross inflammatory response within 1 h, yet when this dose of LPS is injected daily into this same site, tolerance does not develop to the inflammatory activity. Further, when tolerance is induced with daily, repetitive i.v. injections of LPS, there is still a local inflammatory response when a subsequent dose of LPS is given intradermally. 13 The mechanisms involved in the induction of endotoxin tolerance have been studied ex vivo following the administration of LPS in vivo to human subjects. 6, 134 When PBMCs from cancer patients given daily LPS were re-stimulated ex vivo, there was an increase in TNF-a levels which differed from the decrease in circulating levels of that cytokine in vivo. 6 This increase in TNF-a was not observed when PBMCs from healthy volunteers given an infusion of LPS was studied ex vivo. 134 Griesman speculated that as the hepatic Kupffer cell became refractory to LPS, then LPS would be diverted to less refractory, extrahepatic sites. 13, 23 Ample data have shown that different organs will respond differently to the LPS. For example, there is a diminished IL-10 response in the lung of LPS tolerant rats compared to that same animal's response in the liver. 135 Salkowski et al. have demonstrated different chemokine responses in liver and lung. 136 The relative importance of these differences in organ-specific responses to LPS is not clear.
Perhaps the most intriguing example of organ-specific responses to LPS is that of the CNS. 137 In the absence of direct injection of LPS into the CNS, there is no endotoxin tolerance at that site despite the induction of LPS tolerance outside the CNS. 137 The thermoregulatory centers do respond to endogenous pyrogen during tolerance. 26 In the absence of vagal stimulation of the liver, there is no LPS tolerance induction. 138 One potential mechanism for this observation was recently reported. The CNS can respond to LPS through nicotinic cholinergic receptors expressed on macrophages in the periphery which detect acetylcholinemediated efferent signals carried through the vagus nerve. These vagally-stimulated macrophages have a reduced cytokine response. 139 In the CNS, nitric oxide appears to play a role in LPS tolerance. 140 The potential role of the neuro-immuno-endocrine axis in endotoxin tolerance has been under considerable study. Animals that are tolerant to endotoxin are also resistant to epinephrine. 141 The epinephrine tolerant state increases the survival from LPS-induced shock raising the possibility of cross-tolerance between LPS and epinephrine; however, the cytokine responses (TNF-a, IL-6 and IL-10) differ in the two conditions. 109 Adrenalectomized mice are exquisitely sensitive to endotoxin, but one can induce tolerance in adrenalectomized mice. 142 Another study, however, was to induce LPS tolerance unless exogenous steroids were given. 143 
In vitro versus in vivo studies
A considerable amount of the data generated comes from in vitro systems in which the expression of membrane surface receptors, intracellular signalling pathways, transcription factor migration and gene activation and transcription events can be carefully evaluated under various conditions of LPS exposure. Some have suggested that such systems are useful surrogates to further our understanding of LPS tolerance in vivo. 96 If that were the case, it is appropriate to consider the obvious limits to the type and perhaps relevance of the information obtained.
Usually, one type of cell (e.g. primary macrophage or macrophage cell lines) or cells from one anatomic site (e.g. spleen, peritoneum) is studied. While the focus on the macrophage is well justified, the responses of macrophages from different sites may vary. 135 For example, Griesman speculated that during endotoxin tolerance the important Kupffer cells becomes resistant to the activity of LPS and, therefore, the response of macrophages in other, non-hepatic tissues may assume increased importance. 25 Further, macrophages from different anatomical sites may respond differently (see above).
The influence of additional cells must be adequately considered. For example, if an increase in IFN-g plays a role in the endotoxin tolerant state, then lymphocytes (including gd T lymphocytes) or NK-cells might be included in the cultures. In vivo studies have the obvious advantage of permitting various cellular interactions to occur.
In in vitro systems, there is no change in the concentration of LPS over the course of the experiment. This is not the case in vivo, where the concentration of the administered LPS undergoes changes both in levels and in the tissue distribution. These changes may greatly alter the response of a particular cell to the LPS.
Similarly, in the in vitro system the secreted products from the LPS-stimulated cells, if not broken down, accumulate with time. Such products may be cleared in in vivo systems. Thus it may be difficult to discern the differential effects of higher or lower levels of elicited mediators on the system. This persistence also may permit the synergistic interaction of various mediators that might not occur in vivo.
In vivo, there is a well-described sequence of cytokine expression following LPS treatment with a maximal expression for each cytokine followed by a return to baseline. Such a response may avoid the simultaneous expression of cytokine combinations that otherwise may exhibit synergistic responses (e.g. TNF-a and IFN-g on IL-1 51 ) that may have adverse consequences. This is not the case in vitro.
Finally, after LPS administration in vivo there are marked changes in the composition of the amount and avidity of serum proteins and lipoproteins which greatly affect the bioactivity of the LPS. 144, 145 This is often not considered during in vitro studies. In summary, through in vitro experiments much can be learned about the behavior of molecules during LPS exposure; however, one must exercise care in applying the findings to an in vivo situation.
PHYSIOLOGICAL SIGNIFICANCE AND CLINICAL
IMPLICATIONS OF ENDOTOXIN TOLERANCE
The teleological question posed many years ago by Bennett is still germane: is there any physiological role for endotoxin tolerance in our response to the world around us so that it might it be applied to clinical medicine, or is it simply a spectacular, yet irrelevant, experimental event? If the latter, then analysis of experimental details in studying endotoxin tolerance is largely an academic exercise -it is easily possible to induce tolerance through many avenues, and the specific regimens used are not critical. If, however, there might be some clinical application of endotoxin tolerance, then it is incumbent to evaluate rigorously the various experimental methods employed.
Initially, endotoxin tolerance was a complication to be avoided while utilizing one treatment for cancer or during fever therapy with a typhoid vaccine. With the need for adjunctive therapies for the prevention and treatment of sepsis, some investigators suggested that the induction of endotoxin tolerance would render a patient less susceptible to the pathological effects of circulating endotoxin and the accompanying tissue injury and organ dysfunction, 146 thereby reducing the exaggerated immune response characteristic of the septic state.
Before one employs this strategy clinically, however, it is necessary to return to the vexing question whether there is any relationship between the endotoxin tolerant state and host defenses against viable, potentially pathogenic microbes. This consideration is critically important in choosing the properties of the ideal therapeutic agent. If there is no relationship between the LPS non-responsive state (e.g. tolerance) and antimicrobial host defenses, then one can completely block the LPS responses without regard to possible effects on antimicrobial host defenses.
If, on the other hand, there is a relationship between LPSinitiated responses and antimicrobial host defenses, then it will be necessary to revisit some of the unresolved questions of an earlier era: (i) is there a common mechanism for the two; (ii) what is the role of RES clearance and/or the Kupffer cell; and (iii) do the studies performed in rabbits and rodents apply to humans? These questions must be reconsidered in the light of our current knowledge of the various molecular responses to LPS.
There was ample evidence a half century ago that regimens of LPS administration that could induce endotoxin tolerance also enhanced host defenses against various pathogens, 10-12 and investigators continue to show such protection against bacterial and fungal pathogens. 84, 147 Several decades ago, the Urbascheks suggested that it may be possible to calibrate a level of Kupffer cell stimulation by LPS that would retain or enhance its antibacterial activity while minimizing its toxic responses. 148 Since then reagents for human use have been developed that have attempted to achieve those goals. Monophosphoryl lipid A (MPLA), an attenuated derivative of lipid A that is 1000-fold less pyrogenic for rabbits than the parent LPS, 149 can induce endotoxin tolerance and enhance non-specific resistance within 24 h of its administration. 85 It does retain some LPS agonist activity as shown by its ability to increase serum CSA and to increase the number of macrophage precursors in the bone marrow, 149 but demonstrates little toxicity at that dose. The TNF-a, IL-6 and IFN-g levels were much lower after MPLA administration than they were following LPS. 149 Similarly, SDZ MRL induced tolerance when given to cancer patients. 150 While there were increases in GCSF and IL-6 levels, the pro-inflammatory cytokine response was much reduced.
If this approach is a useful clinical strategy, however, it will be necessary to address rigorously many of the concerns enumerated above: what dose and regimens will induce tolerance quickly, and maintain that tolerance while preserving antimicrobial host defenses? Importantly, since it is not a static state, the kinetics of the tolerant state would have to be considered so a compensatory, hyporesponsive state does not follow, and the duration of the effect with specific regimens should be known, and methods to monitor the state of that activity identified.
The induction of a hyporesponsiveness to LPS by way of endotoxin tolerance relies on an active response to LPS, even if an attenuated one. It is also possible to induce a hyporesponsiveness to LPS by completely blocking any response to LPS. Non-agonist reagents that are designed to block any response to LPS are being developed. 151 While this strategy might not appear to require consideration of any mechanistic relationship between LPS hyporesponsiveness and antimicrobial defenses, there is concern that such an approach may increase susceptibility to overwhelming infection. Total ablation of the LPS-mediated response, as shown in C3H/HeJ mice that have a defective TLR4 receptor, can reduce the likelihood of LPS-mediated septic death, but at the risk of enhancing the risk of lethal infection. 152, 153 This approach of complete LPS blockade in man theoretically could result in a situation akin to the C3H/HeJ mouse with a risk of overwhelming infection and must be considered.
CONCLUSIONS
With the benefit of over 50 years of research on the phenomenon of endotoxin tolerance, it may now be possible to offer some hypothesis to the question posed by Ivan Bennett at the start of this essay. There may be some physiological significance to endotoxin tolerance in its relationship to antimicrobial host defenses. If tolerance is a protective mechanism from the pathological hyperactivity induced by LPS, 88 then LPS-enhanced host defenses may be an attempt on the part of the host to deal with a pathogen that has evaded normal host defenses. In this view, LPS tolerance may allow additional time for the host to rid itself of the pathogen by LPS-enhanced defenses, while delaying the lethal reactivity to the endotoxin. If that effort is unsuccessful, however, the increasing amounts of LPS generated by the replicating organism can override the tolerance and kill the host.
The subject of endotoxin tolerance is not so much a 'chronic insoluble' problem envisaged by Lewis Thomas or even a 'spectacularly irrelevant' one feared by Bennett, but rather an endlessly fascinating response to a ubiquitous bacterial component. Just as it has changed from an annoying interference of cancer or fever therapy in the 1940s to a physiological event perhaps to be exploited for the treatment of sepsis today, future investigators should remain open to the notion that the phenomenon of endotoxin tolerance may yet be re-incarnated in forms yet to be conceived.
